Hypercalcaemia with Renal Impairment — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Denosumab – as bisphosphonates are contraindicated with creatinine >200
With significant renal impairment (creatinine 200 µmol/L), bisphosphonates require dose adjustment or are relatively contraindicated (zoledronic acid is not recommended with CrCl <35 mL/min). Denosumab (a RANKL inhibitor) does not require renal dose adjustment and is effective for malignancy-associated hypercalcaemia refractory to bisphosphonates or when bisphosphonates are contraindicated by renal impairment. However, calcium monitoring is essential as denosumab can cause severe hypocalcaemia in CKD.
Reference: AMH – 2025 – Bone Modifying Agents; eTG – 2025 – Endocrinology